Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Gastroenterol. Jan 28, 2017; 23(4): 622-628
Published online Jan 28, 2017. doi: 10.3748/wjg.v23.i4.622
Table 1 Baseline patient characteristics n (%)
Total (n = 38)
Age, mean, yr73.7 ± 12.1
Sex, male/female26(68.4)/12(31.6)
Indication of biliary stent
CBD stone19 (50.0)
CBD stricture14 (36.8)
CBD stone with CBD stricture5 (13.2)
Types of stents
Diameter, Fr: 7/10/11.52(5.3)/21(55.3)/15(39.5)
Length, cm: 5/7/913(34.2)/22(57.9)/3(7.9)
Underlying diseases
Chronic pancreatitis4 (10.5)
Liver cirrhosis1 (2.6)
STG BII4 (10.5)
Chronic renal failure2 (5.3)
Cerebrovascular accident5 (13.2)
Table 2 Presenting symptoms and laboratory findings at admission
VariableTotal (n = 38)
Symptoms
Abdominal pain36 (94.7)
Fever20 (52.6)
Jaundice13 (34.2)
Without symptom2 (5.3)
Laboratory findings
WBC, cells/mcL10270.20 ± 4835.67
ALT, IU/L122.50 ± 238.72
GGT, IU/L236 ± 209.18
Total bilirubin, mg/dL2.57 ± 2.19
Amylase, U/L213.74 ± 494.75
Table 3 Complications and outcomes according to biliary stent duration n (%)
VariableTotal1-2 yrOver 2 yrP value
(n = 38)(n = 28)(n = 10)
Age, yr73.7 ± 12.175.6 ± 10.068.3 ± 16.10.104
Sex, male/female26/14(68.4/31.6)19/9(67.9/32.1)7/3 (70/30)1.000
Duration of stent-stay, mo22.6 ± 12.216.4 ± 3.039.7 ± 11.70.001
Complications of stents
Jaundice13 (34.2)11 (39.3)2 (20.0)0.441
Cholangitis36 (94.7)26 (92.9)10 (100.0)1.000
Pancreatitis2 (5.3)1 (3.6)1 (10.0)0.462
Internal migration5 (13.2)3 (10.7)2 (20.0)0.592
Presence of CBD stone35 (92.1)25 (89.3)10 (100.0)0.552
Endoscopic treatment
Stone removal28 (73.7)21 (75.0)7 (70.0)1.000
Stent removal35 (92.1)26 (92.9)9 (90.0)1.000
Stent reinsertion19 (50.0)16 (57.1)3 (15.8)0.269
Additional stent insertion3 (7.9)2 (7.1)1 (10.0)1.000